Randomized multicenter phase 2 study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

Disclosures: MCF has served on an advisory board for ARIAD, received research funding from Sanofi-Aventis, Celgene, and Gilead. SAS has served on advisory boards for Sunesis, and Boehringer Ingelheim. JEL has served on advisory boards for Celgene, Boehringer Ingelheim, Celator, and Seattle Genetics, received research funding from Celgene and Pfizer. PB has served on advisory boards for Amgen, Sanofi, Celgene, Alexion, Incyte, and Seattle Genetics, and travel and accommodation expenses from Amgen, Celgene, Gilead, Novartis, and TetraLogic Pharmaceuticals. MYL has served on advisory boards for Seattle Genetics, Bristol-Myers Squibb, and ARIAD, and speakers Bureau for Millennium and Onyx. IG has served on advisory boards for Boehringer Ingelheim and Spectrum Pharmaceuticals. GLR has stock ownership in Pfizer, Johnson & Johnson, and Walgreens, has received honoraria, and travel and accommodations expenses from Novartis. The remaining authors declare no competing financial interest.

Contributions: JFZ collected the data, performed data analysis and data interpretation, and wrote the report. JEK, ALB, GLR, RFL, JJW, and LAD conceived the study design. ALB and GLR performed statistical analysis. CDG performed histopathologic review. MCF, MRL, LEM, SAS, JEL, PB, MYL, RT, and IG enrolled patients. BDS and JEK enrolled patients, performed data interpretation, and wrote the report. All authors reviewed and finalized the report.